These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 18560594)

  • 1. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.
    Dylla SJ; Beviglia L; Park IK; Chartier C; Raval J; Ngan L; Pickell K; Aguilar J; Lazetic S; Smith-Berdan S; Clarke MF; Hoey T; Lewicki J; Gurney AL
    PLoS One; 2008 Jun; 3(6):e2428. PubMed ID: 18560594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
    Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
    Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
    Arcaroli JJ; Powell RW; Varella-Garcia M; McManus M; Tan AC; Quackenbush KS; Pitts TM; Gao D; Spreafico A; Dasari A; Touban BM; Messersmith WA
    Mol Oncol; 2012 Jun; 6(3):370-81. PubMed ID: 22521243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin attenuates resistance to irinotecan via induction of apoptosis of cancer stem cells in chemoresistant colon cancer cells.
    Su P; Yang Y; Wang G; Chen X; Ju Y
    Int J Oncol; 2018 Sep; 53(3):1343-1353. PubMed ID: 29956726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells.
    Sharma A; Vatapalli R; Abdelfatah E; Wyatt McMahon K; Kerner Z; A Guzzetta A; Singh J; Zahnow C; B Baylin S; Yerram S; Hu Y; Azad N; Ahuja N
    PLoS One; 2017; 12(4):e0176139. PubMed ID: 28445481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
    Agrawal S; Woźniak M; Łuc M; Makuch S; Pielka E; Agrawal AK; Wietrzyk J; Banach J; Gamian A; Pizon M; Ziółkowski P
    Sci Rep; 2019 Nov; 9(1):16647. PubMed ID: 31719636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral functional heterogeneity and chemotherapy.
    Sipos F; Constantinovits M; Műzes G
    World J Gastroenterol; 2014 Mar; 20(10):2429-32. PubMed ID: 24627580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells.
    Mukohyama J; Isobe T; Hu Q; Hayashi T; Watanabe T; Maeda M; Yanagi H; Qian X; Yamashita K; Minami H; Mimori K; Sahoo D; Kakeji Y; Suzuki A; Dalerba P; Shimono Y
    Cancer Res; 2019 Oct; 79(20):5151-5158. PubMed ID: 31416845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New chemotherapeutic strategies in colorectal cancer.
    Moehler M; Teufel A; Galle PR
    Recent Results Cancer Res; 2005; 165():250-9. PubMed ID: 15865041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
    Ayadi M; Bouygues A; Ouaret D; Ferrand N; Chouaib S; Thiery JP; Muchardt C; Sabbah M; Larsen AK
    Oncotarget; 2015 Jul; 6(21):18518-33. PubMed ID: 26041882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE; Kollander R; Sreerama L; Kiang DT
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480.
    Butler SJ; Richardson L; Farias N; Morrison J; Coomber BL
    Biochem Biophys Res Commun; 2017 Aug; 490(1):29-35. PubMed ID: 28576498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
    Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
    Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.